Intact PTH Combined With the PTH Ratio for Diagnosis of Bone Turnover in Dialysis Patients: A Diagnostic Test Study

American Journal of Kidney Diseases

Volumn 55, Issue 5, 2010, Pages 897-906

  Herberth, Johann ^a   Branscum, Adam J ^a   Mawad, Hanna ^a   Cantor, Tom ^b   Monier Faugere, Marie Claude ^a   Malluche, Hartmut H ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Scantibodies Laboratory Inc   (United States)

Author keywords

bone biopsy; bone turnover; chronic kidney disease; classification and regression tree (CART) analysis; dialysis; Intact parathyroid hormone (PTH); predictive value; PTH 1 84; PTH ratio

Indexed keywords

PARATHYROID HORMONE;

ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD SAMPLING; BONE TURNOVER; CAUCASIAN; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; PARATHYROID HORMONE BLOOD LEVEL;

ALGORITHMS; CALCIUM; HUMANS; IMMUNOASSAY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PHOSPHORUS; PREDICTIVE VALUE OF TESTS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 77951622815     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.041     Document Type: Article

References (46)

1. Malluche H.H., and Monier-Faugere M.C. Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 65 4 (2006) 235-242
2. Moe S., Drueke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 69 11 (2006) 1945-1953
3. Martin K.J., Olgaard K., Coburn J.W., et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 43 3 (2004) 558-565
4. Malluche H.H., and Monier-Faugere M.C. The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol. 4 (1994) 1631-1642
5. Malluche H.H., and Faugere M.C. Atlas of Mineralized Bone Histology (1986), Karger, New York, NY
6. Hruska K.A., and Teitelbaum S.L. Renal osteodystrophy. N Engl J Med. 33 (1995) 166-174
7. Berson S.A., and Yalow R.S. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab. 28 7 (1968) 1037-1047
8. Fischer J.A., Binswanger U., and Dietrich F.M. Human parathyroid hormone. Immunological characterization of antibodies against a glandular extract and the synthetic amino-terminal fragments 1-12 and 1-34 and their use in the determination of immunoreactive hormone in human sera. J Clin Invest. 54 6 (1974) 1382-1394
9. Manning R.M., Hendy G.N., Papapoulos S.E., and O'Riordan J.L. Development of homologous immunological assays for human parathyroid hormone. J Endocrinol. 85 1 (1980) 161-170
10. Mayer G.P., Keaton J.A., Hurst J.G., and Habener J.F. Effects of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous blood. Endocrinology 104 6 (1979) 1778-1784
11. Segre G.V., Niall H.D., Sauer R.T., and Potts Jr. J.T. Edman degradation of radioiodinated parathyroid hormone: application to sequence analysis and hormone metabolism in vivo. Biochemistry 16 11 (1977) 2417-2427
12. Martin K.J., Hruska K.A., Freitag J.J., Klahr S., and Slatopolsky E. The peripheral metabolism of parathyroid hormone. N Engl J Med. 301 20 (1979) 1092-1098
13. Brown R.C., Aston J.P., Weeks I., and Woodhead J.S. Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab. 65 3 (1987) 407-414
14. Nussbaum S.R., Zahradnik R.J., Lavigne J.R., et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 33 8 (1987) 1364-1367
15. Qi Q., Monier-Faugere M.C., Geng Z., and Malluche H.H. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 26 4 (1995) 622-631
16. Wang M., Hercz G., Sherrard D.J., Maloney N.A., Segre G.V., and Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis. 26 5 (1995) 836-844
17. Brossard J.H., Cloutier M., Roy L., Lepage R., Gascon-Barre M., and D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 81 11 (1996) 3923-3929
18. Langub M.C., Monier-Faugere M.C., Wang G., Williams J.P., Koszewski N.J., and Malluche H.H. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144 4 (2003) 1135-1138
19. Herberth J., Fahrleitner-Pammer A., Obermayer-Pietsch B., et al. Changes in total parathyroid hormone (PTH), PTH-(1-84) and large C-PTH fragments in different stages of chronic kidney disease. Clin Nephrol. 65 5 (2006) 328-334
20. Gao P., Scheibel S., D'Amour P., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 16 (2001) 605-614
21. John M.R., Goodman W.G., Gao P., Cantor T.L., Salusky I.B., and Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 84 11 (1999) 4287-4290
22. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 42 4 suppl 3 (2003) S1-S201
23. Souberbielle J.C., Boutten A., Carlier M.C., et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 70 2 (2006) 345-350
24. Joly D., Drueke T.B., Alberti C., et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 51 6 (2008) 987-995
25. Cantor T., Yang Z., Caraiani N., and Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem. 52 9 (2006) 1771-1776
26. Herberth J., Faugere M.C., Mawad H., et al. The 5 most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patients. Clin Nephrol. 72 1 (2009) 5-14
27. Malluche H.H., Meyer W., Sherman D., and Massry S.G. Quantitative bone histology in 84 normal American subjects. Micromorphometric analysis and evaluation of variance in iliac bone. Calcif Tissue Int. 34 5 (1982) 449-455
28. Breiman L., Friedman J., Stone C.J., and Olshen R.A. Classification and Regression Trees (1984), Wadsworth Int Group, Belmont, CA
29. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., and de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 15 7 (2004) 1943-1951
30. Adragao T., Ferreira A., Frazao J., et al. Vascular calcifications and bone turnover in hemodialysis patients. [abstract]. Nephrol Dial Transplant. 21 suppl iv (2006) S292
31. Parfitt A.M. The physiologic and clinical significance of bone histomorphometric data. In: Recker R.R. (Ed). Bone Histomorphometry: Techniques and Interpretation (1983), CRC Press Inc, Boca Raton, FL 143-224
32. Eriksen E.F. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev. 7 4 (1986) 379-408
33. Parfitt A.M., Drezner M.K., Glorieux F.H., et al. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res. 6 (1987) 595-610
34. Monier-Faugere M.C., Geng Z., Mawad H., et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int. 60 4 (2001) 1460-1468
35. Malluche H.H., Mawad H., and Monier-Faugere M.C. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?. Nephrol Dial Transplant. 19 suppl 1 (2004) i9-i13
36. Baker L.R., Abrams L., Roe C.J., et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int. 35 2 (1989) 661-669
37. Malluche H.H., and Monier-Faugere M.C. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl. 38 (1992) S62-S67
38. Hernandez J.D., Wesseling K., and Salusky I.B. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy. Semin Dial. 18 4 (2005) 290-295
39. Malluche H.H., Monier-Faugere M.C., Wang G., et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 69 4 (2008) 269-278
40. Malluche H.H., Faugere M.C., Fanti P., and Price P.A. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int. 26 6 (1984) 869-874
41. Hruska K.A., Mathew S., and Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res. 97 2 (2005) 105-114
42. Orita Y., Yamamoto H., Kohno N., et al. Role of osteoprotegerin in arterial calcification. development of new animal model. Arterioscler Thromb Vasc Biol. 27 9 (2007) 2058-2064
43. Sawaya B.P., Butros R., Naqvi S., et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int. 64 2 (2003) 737-742
44. Salusky I.B., Goodman W.G., Kuizon B.D., et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int. 63 5 (2003) 1801-1808
45. Coen G., Bonucci E., Ballanti P., et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 40 2 (2002) 348-354
46. Fehmi H., Osman Y., Bhat S., et al. Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio. Clin Nephrol. 71 3 (2009) 267-275